A U.S. analysis found inhalers for asthma and COPD generated nearly 25 million metric tons of CO₂ emissions between 2014 and ...

Amneal Pharmaceuticals recently received U.S. FDA approvals for its generic versions of RESTASIS® (cyclosporine ophthalmic emulsion 0.05%) and PROAIR® HFA (albuterol sulfate inhalation aerosol 90 mcg) ...

Amneal Pharmaceuticals received Food and Drug Administration approval for its albuterol sulfate inhalation aerosol to treat bronchospasm in people with reversible obstructive airway disease. The ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Tuesday that the U.S. Food and Drug Administration has approved its albuterol sulfate inhalation aerosol, a generic equivalent ...

Represents second complex respiratory therapeutic product approval in Q4 2025BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX ...

GSK plc announced positive phase III data from its clinical programme to develop a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). Data confirm that the formulation ...

GSK plc (LSE/NYSE:GSK) announced Wednesday that its next-generation low carbon version of the Ventolin (salbutamol) metered dose inhaler (MDI) achieved positive results in pivotal phase III clinical ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. GlaxoSmithKline ( (GB:GSK)) has provided ...

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...